BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19293288)

  • 1. Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo.
    Ishii K; Imamura T; Iguchi K; Arase S; Yoshio Y; Arima K; Hirano K; Sugimura Y
    Endocr Relat Cancer; 2009 Jun; 16(2):415-28. PubMed ID: 19293288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in predicting tumorigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme.
    Kanai M; Ishii K; Kanda H; Ogura Y; Kise H; Arima K; Sugimura Y
    Cancer Sci; 2008 Dec; 99(12):2435-43. PubMed ID: 19018772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
    Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME
    Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
    Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
    Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
    Tørring N; Jørgensen PE; Sørensen BS; Nexø E
    Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
    Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
    Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer.
    Carstens RP; Eaton JV; Krigman HR; Walther PJ; Garcia-Blanco MA
    Oncogene; 1997 Dec; 15(25):3059-65. PubMed ID: 9444954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterization of LNCaP sublines differing in hormone sensitivity.
    Iguchi K; Ishii K; Nakano T; Otsuka T; Usui S; Sugimura Y; Hirano K
    J Androl; 2007; 28(5):670-8. PubMed ID: 17409465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
    Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells.
    Ishii K; Mizokami A; Tsunoda T; Iguchi K; Kato M; Hori Y; Arima K; Namiki M; Sugimura Y
    J Cell Biochem; 2011 Dec; 112(12):3604-11. PubMed ID: 21809373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
    Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
    Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells.
    Robbins SE; Shu WP; Kirschenbaum A; Levine AC; Miniati DN; Liu BC
    Prostate; 1996 Dec; 29(6):362-70. PubMed ID: 8977633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
    Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
    Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
    Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
    Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.